JMP Securities analyst Constantine Davides initiated coverage of OptimizeRx with an Outperform rating and $15 price target. The company is a provider of digital marketing solutions to healthcare providers, the analyst tells investors in a research note. The company’s Dynamic Audience Activation Platform rollout is still in the early innings, but momentum is building, says the firm. It sees a compelling entry point at current share levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
- OptimizeRx cuts FY24 revenue view to at least $100M from at least $110M
- OptimizeRx backs FY23 revenue view at least $68M-$70M, consensus $69.85M
- OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
- OptimizeRx Powers Walmart’s ‘Specialty Pharmacies of the Community’ Outreach Effort
